TABLE 4.
Association of TMAO with all‐cause mortality, assessed with Cox proportional hazard ratios in subjects without NAFLD (FLI < 60)
|
TMAO per 1 Ln SD increment |
T1 | T2 | T3 | ||||
|---|---|---|---|---|---|---|---|
| Participants, n | 3694 | 1232 | 1231 | 1231 | |||
| Events, n | 174 | 51 | 62 | 61 | |||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
| Crude Model | 1.14 (0.98, 1.33) | .09 | (ref) | 1.22 (0.84, 1.76) | .30 | 1.18 (0.81, 1.71) | .39 |
| Model 1 | 1.02 (0.87, 1.20) | .81 | (ref) | 0.86 (0.59, 1.24) | .41 | 0.90 (0.62, 1.31) | .59 |
| Model 2 | 1.07 (0.91, 1.26) | .41 | (ref) | 0.90 (0.62, 1.30) | .56 | 0.94 (0.65, 1.37) | .75 |
| Model 3 | 1.07 (0.91, 1.25) | .42 | (ref) | 0.90 (0.62, 1.31) | .56 | 0.94 (0.65, 1.37) | .75 |
| Model 4 | 1.07 (0.91, 1.26) | .42 | (ref) | 0.91 (0.62, 1.32) | .61 | 0.95 (0.65, 1.39) | .78 |
Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs) and P values. Model 1: Model adjusted for age + sex. Model 2: Model 1 + SBP + smoking status + alcohol consumption + cancer history + glucose lowering medication + lipid lowering medication. Model 3: Model 2 + TC + HDL‐C + glucose. Model 4: Model 3 + albuminuria + reduced eGFR (<90 ml/min/1.73 m2).